Drug Combo Shuts Down Stem Cells, Tumor Growth in Lung Cancer
JACKSONVILLE, Fla. — Researchers on Mayo Clinic’s Florida campus have shut down one of the most common and lethal forms of lung cancer by combining the rheumatoid arthritis drug auranofin with an experimental targeted agent. The combination therapy worked in a laboratory study to stop lung adenocarcinoma associated with mutation of the KRAS gene. The [...]
Source: Mayo Clinic Florida News - Category: Hospital Management Source Type: news
More News: Adenocarcinoma | Arthritis | Cancer | Cancer & Oncology | Genetics | Hospital Management | Laboratory Medicine | Lung Cancer | Rheumatoid Arthritis | Rheumatology | Stem Cell Therapy | Stem Cells | Study